Resolute ZES (zotarolimus-eluting stent) / Medtronic 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


1234567891011»
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Journal:  OCT-Guided covered stent implantation for acquired coronary aneurysm after bioresorbable vascular scaffold: case report. (Pubmed Central) -  Mar 29, 2025   
    Optical coherence tomography (OCT) confirmed a 5.88?mm aneurysm, which was treated with a PK Papyrus covered stent, while the proximal LAD stenosis was addressed with a Resolute Onyx drug-eluting stent (DES)...At the nine-month follow-up, the patient remained symptom-free. This case highlights the utility of OCT in evaluating CAAs and guiding covered stent deployment, while prolonged DAPT may help reduce the risk of very late stent thrombosis and future ischemic events, though further studies are needed.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Retrospective data, Journal:  Use of Onyx Frontier (Pubmed Central) -  Oct 21, 2024   
    Trial completion date: Jul 2025 --> Jul 2028 | Trial primary completion date: Jul 2025 --> Jul 2028 This is the largest multicenter cohort study demonstrating the feasibility and safety of using the Onyx Frontier
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Journal:  Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Stent Implantation. (Pubmed Central) -  Oct 4, 2024   
    This is the largest multicenter cohort study demonstrating the feasibility and safety of using the Onyx Frontier Machine learning using the X-learner approach identifies patients with acute coronary syndrome who may benefit from abbreviated DAPT after drug-eluting stent implantation, laying the groundwork for personalized antiplatelet therapy.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Clinical, Journal:  One-Month Dual Antiplatelet Therapy in High Bleeding Risk Asian Patients Undergoing Percutaneous Coronary Intervention?- Onyx ONE Clear 2-Year Results. (Pubmed Central) -  Aug 12, 2024   
    P=N/A
    One-month dual antiplatelet therapy (DAPT) in high bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) with the Resolute OnyxTM zotarolimus-eluting stents (ZES) is safe and effective...However, there were significantly fewer Bleeding Academic Research Consortium types 3-5 bleeding events in the Asian vs. non-Asian cohort (4% vs. 9%; P=0.007), despite similar bleeding risk profiles after matching. After propensity score matching, HBR patients from Asian countries undergoing PCI treated with 1-month DAPT had similar ischemic outcomes but fewer bleeding events between 1 month and 2 years compared with patients from non-Asian countries.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Trial primary completion date:  TARGET-IV_NA: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial (clinicaltrials.gov) -  Jul 24, 2024   
    P=N/A,  N=1720, Active, not recruiting, 
    These results support the longer-term safety and effectiveness of Resolute Onyx ZES to treat bifurcation lesions that are amenable to a planned provisional stenting technique. Trial primary completion date: Jun 2024 --> Dec 2023
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion, Combination therapy:  Bioflow-DAPT Study (clinicaltrials.gov) -  Jun 7, 2024   
    P4,  N=1948, Completed, 
    ZES and EES have similar safety and efficacy at short, intermediate, and long-term follow-ups. Active, not recruiting --> Completed
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial primary completion date:  ONYSOVER: Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT (clinicaltrials.gov) -  Jun 3, 2024   
    P=N/A,  N=30, Recruiting, 
    Active, not recruiting --> Completed Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Dec 2025
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial primary completion date, HEOR:  IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact (clinicaltrials.gov) -  May 16, 2024   
    P=N/A,  N=3100, Recruiting, 
    FP-EES demonstrated the most favorable antithrombotic and anti-inflammatory profile regardless of the different experimental designs. Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Apr 2024 --> Apr 2027
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Ten-year major clinical outcomes between first- and second-generation drug-eluting stents in hypertensive patients underwent percutaneous coronary intervention (Station 7 - Research Gateway) -  May 14, 2024 - Abstract #ESC2024ESC_2675;    
    Finally, a total of 1,631 eligible hypertensive patients who underwent PCI with 1G-DES (paclitaxel-, sirolimus-eluting stent, n = 715) or 2G-DES (zotarolimus [endeavor, endeavor resolute]- or everolimus-eluting stent [promus element, xience], n = 916) were enrolled. In our single-center, all-comer registry, 2G-DES had better efficacy especially repeat revascularization and MACE as compared with 1G-DES in hypertensive patients during 10-year follow-up periods.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Drug eluting stents trigger the secretion of inflammatory proteins in an experimental in vitro study (Station 9 - Research Gateway) -  May 14, 2024 - Abstract #ESC2024ESC_1118;    
    Furthermore, we provided first insights into the composition of the inflammosome in response to DES. A triggered inflammation may increase the vulnerability for complications and the failure of the DES.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Journal:  The resolute Onyx in TIA management (ROTIA). (Pubmed Central) -  Apr 23, 2024   
    Limitations include the retrospective and single-center nature of this study. Future prospective, multi-center, randomized trials with extended observation periods are needed.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date:  A Safety and Efficacy Study of Dissolve (clinicaltrials.gov) -  Feb 20, 2024   
    P=N/A,  N=277, Active, not recruiting, 
    Future prospective, multi-center, randomized trials with extended observation periods are needed. Trial completion date: Dec 2023 --> Dec 2025
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion date, Trial primary completion date:  IRIS-Onyx Cohort in the IRIS-DES Registry (clinicaltrials.gov) -  Dec 19, 2023   
    P=N/A,  N=4500, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Sep 2027 --> Dec 2029 | Trial primary completion date: Sep 2023 --> Dec 2025
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Enrollment closed:  TARGET-IV_NA: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial (clinicaltrials.gov) -  Oct 19, 2023   
    P=N/A,  N=1720, Active, not recruiting, 
    The study was funded by Elixir Medical. Recruiting --> Active, not recruiting
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion:  China Resolute Integrity 34/38 mm Study (clinicaltrials.gov) -  Oct 10, 2023   
    P=N/A,  N=40, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Journal:  Prognostic Impact of Drug-Coated Balloons in Patients With Diabetes Mellitus: A Propensity-Matched Study. (Pubmed Central) -  Sep 9, 2023   
    Active, not recruiting --> Completed Paclitaxel-eluting balloon represented the most common strategy in the DCB group, whereas Zotarolimus-eluting stents were used in half of the DES population...Major ischemic end points were slightly increased in patients treated with DCB, whereas overall death was significantly reduced (3.6% vs 10.9%; adjusted hazard ratio [95% confidence interval]
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Enrollment closed, Trial completion date, Trial primary completion date:  Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) (clinicaltrials.gov) -  Sep 7, 2023   
    P=N/A,  N=2400, Active, not recruiting, 
    BIO-RESORT trial: clinicaltrials.gov (NCT01674803); BIONYX trial: clinicaltrials.gov (NCT02508714). Recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> Aug 2028 | Trial primary completion date: Dec 2023 --> Aug 2024
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
    Journal:  Stent expansion in calcified coronary chronic total occlusions: (Pubmed Central) -  Aug 1, 2023   
    Dp-ZES was associated with a lower incidence of high relative focal stent recoil, in noncalcific CTOs. Balloon deficit might be considerate as a surrogate for stent expansion in calcified CTOs.
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Journal:  A technology evaluation of the Onyx Frontier drug-eluting stent. (Pubmed Central) -  Jun 19, 2023   
    Onyx Frontier represents the latest iteration within the family of zotarolimus-eluting stents (ZES), designed for the treatment of coronary artery disease...The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions.